{"entity":{"id":"nct07405151","kind":"trial","name":"A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)","aka":[],"tldr":"A phase 1/2 trial of I-DXd in oesophageal cancer, run by Merck Sharp & Dohme LLC, now recruiting.","summary":"A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F) is a phase 1/2 interventional study registered as NCT07405151 by Merck Sharp & Dohme LLC, with 60 participants planned, started 2026-03-27 and due to reach its primary completion in 2027-06-12. Interventions recorded: I-DXd and Rescue Medication.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07405151","url":"https://clinicaltrials.gov/study/NCT07405151"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["esophageal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["merck","daiichi-sankyo"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07405151","phase":"1/2","setting":"A Phase 2 Open-Label, Umbrella Platform Design Study of Investigational Agent(s) in Participants With 2L/3L Unresectable Locally Advanced or Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06F","sponsor":"Merck Sharp & Dohme LLC","enrolled":60,"outcomes":[]},"route":"/trials/nct07405151/","neighbours":{"cancer":[{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"}],"company":[{"id":"daiichi-sankyo","kind":"company","name":"Daiichi Sankyo","route":"/companies/daiichi-sankyo/"},{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}